Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Elena Portacolone joins Ethics Talk to discuss her article, coauthored with Daisy Elise Feddoes: “Should Artificial Intelligence Play a Role in Cultivating Social Connections Among Older Adults?”
Clinical case and commentary on how physicians should respond when confronted by medication requests from parents of children with mood and concentration disorders.
Anne-Marie Laberge, MD, MPH and Wylie Burke, MD, PhD
Two physicians examine the risks of testing minor children for late-onset genetic diseases when there is no current benefit and explain why several medical associations oppose the practice.